Today’s drug discovery strategies require candidate compounds to fail early and cheaply in the discovery stage, rather than late and expensively in the clinical phase. Testing compounds in physiologically relevant model systems and leveraging information from image-based screens are ways to focus on those compounds that give rise to the right phenotypic changes without undesirable effects on the system.

High Content Screening using detailed multiparametric assays together with powerful data visualization provides a promising way to achieve this goal and turn phenotypic data into robust discoveries.

In our White Paper learn about:

• Why you should consider phenotypic vs. target based strategies
• Challenges you should be aware of
• How to maximize your return